MedTrace Logo

Immune Monitoring on Sipuleucel-T

NCT02237170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2017-01-04

No results posted yet for this study

Summary

The purpose of this protocol is perform comprehensive immune monitoring studies in patients with castration-resistant prostate cancer receiving Sipuleucel-T in an effort to better understand the mechanism of action of this treatment.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Matthew Galsky, MD · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237170 on ClinicalTrials.gov